Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidnarulex and Talazoparib in mCRPC
NCT05425862Phase 1Terminated
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pidnarulex in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Oct 2022; status: terminated.
02
Drugs
pidnarulex
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05425862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425862.